newsfilter
← Latest News
GlobeNewswire·

Field Trip Announces First Dosings in Phase I Clinical Study of FT-104

- First Dosings completed in Australia- Provides Update on Pending Spin-Out and Renaming to Reunion Neurosciences- Announces 5:1 Share Consolidation Ratio TORONTO, July 21, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, FTRP.WT, NASDAQ:F